Obstet Gynecol Sci.  2013 May;56(3):176-181.

Comparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women

• Lee JH
• Jee BC
• Suh CS
• Kim SH
• Choi YM
• Kim JG
• Moon SY

Abstract

OBJECTIVE
To assess the efficacies of once-weekly bisphosphonates on bone mineral density (BMD) gains in Korean women aged 50 years or more.
METHODS
We selected 166 patients who received: alendronate 70 mg (n=48), alendronate 70 mg + cholecalciferol 2,800 IU (n=31) or risedronate 35 mg (n=87) for one year. The baseline BMD and the % changes of BMD at one-year were compared among the three medication groups.
RESULTS
The menopausal status and number of women with osteoporosis was not different among the three groups, but mean age of women was significantly lower in alendronate group. Baseline BMD at L1-4 and femur neck (FN) was similar, but baseline BMD at femur total (FT) was significantly lower in alendronate group. After one-year use, the median % changes of BMD at three sites were similar among the three groups; however, the median values were highest in alendronate + cholecalciferol group (L1-4: 4.48%, 6.74%, and 4.50%; FT: 2.09%, 3.70%, and 2.31%; FN: 3.05%, 3.79%, and 2.03%).
CONCLUSION
Among three once-weekly bisphosphonates, BMD gains were highest after one-year use of alendronate+cholecalciferol, although statistically not significant.

Keyword

Alendronate; Bisphosphonate; Bone mineral density; Cholecalciferol; Risedronate

MeSH Terms

Aged
Alendronate
Bone Density
Cholecalciferol
Diphosphonates
Etidronic Acid
Female
Femur
Femur Neck
Humans
Osteoporosis
Risedronate Sodium
Alendronate
Cholecalciferol
Diphosphonates
Etidronic Acid

Figure

• 

  Fig. 1 Percent changes of bone mineral density at three sites after one-year use of medications (horizontal solid line within the box indicates the median, the box means 75 and 25 percentile, respectively, and upper and lower bar indicate 95 and 5 percentile, respectively).

Reference

1. Poole KE, Compston JE. Osteoporosis and its management. BMJ. 2006. 333:1251–1256.

2. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone. 2004. 34:599–604.

3. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995. 333:1437–1443.

4. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998. 280:2077–2082.

5. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004. 350:1189–1199.

6. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002. 23:508–516.

7. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999. 282:1344–1352.

8. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002. 23:517–523.

9. Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin. 2003. 19:383–394.

10. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005. 20:141–151.

11. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-international. Clin Drug Investig. 2006. 26:63–74.

12. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract. 2008. 62:575–584.

13. Chung HY, Chin SO, Kang MI, Koh JM, Moon SH, Yoon BK, et al. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. Clin Endocrinol (Oxf). 2011. 74:699–704.

14. Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc. 2007. 55:752–757.

15. Yoon JW, Lee BK, Song YC, Kim JY, Shin HY, Lee YH, et al. A comparison of effectiveness and compliance among alendronate pharmaceutical products in Koreans. Korean J Clin Pharm. 2008. 18:114–119.

16. Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin. 2006. 22:1745–1755.